[{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"9e786c9b-5753-46e4-84c2-5d48fa205166","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953104","created_at":"2021-07-07T12:53:55.344Z","updated_at":"2025-02-25T17:37:12.423Z","phase":"Phase 2","brief_title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","source_id_and_acronym":"NCT04953104","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ARID1A • CXCL13","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"74efc10e-be1f-4844-92ec-58390aaca810","acronym":"","url":"https://clinicaltrials.gov/study/NCT05698147","created_at":"2024-06-17T20:38:06.195Z","updated_at":"2024-07-02T16:34:25.656Z","phase":"Phase 1/2","brief_title":"Selinexor in Combination With MTX+Ritu to Treat R/R CNSL","source_id_and_acronym":"NCT05698147","lead_sponsor":"Tong Chen, MD","biomarkers":" IL6 • CXCL13 • IL10","pipe":"","alterations":" ","tags":["IL6 • CXCL13 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-17"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"85405089-6d39-4ea0-95fd-53171a6a6a99","acronym":"","url":"https://clinicaltrials.gov/study/NCT05894889","created_at":"2023-06-09T09:09:10.728Z","updated_at":"2025-02-25T16:18:52.759Z","phase":"Phase 2","brief_title":"Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC","source_id_and_acronym":"NCT05894889","lead_sponsor":"Peking University","biomarkers":" EGFR • ALK • CD8 • PD-1 • CXCL13","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • ALK • CD8 • PD-1 • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-05"},{"id":"98a4f025-5ee8-4f15-ae0b-6980e94aaeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238637","created_at":"2023-11-19T10:15:04.491Z","updated_at":"2025-02-25T15:09:02.238Z","phase":"Phase 2","brief_title":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","source_id_and_acronym":"NCT04238637","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-18"},{"id":"b75c8e0c-7a34-42e8-acb6-f56117fba765","acronym":"","url":"https://clinicaltrials.gov/study/NCT03542266","created_at":"2022-11-13T19:37:00.102Z","updated_at":"2025-02-25T14:27:01.502Z","phase":"Phase 2","brief_title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03542266","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 07/25/2022","study_completion_date":" 07/25/2022","last_update_posted":"2023-08-22"},{"id":"7e21b1c1-21f0-4b37-a171-fa51196f862e","acronym":"IMMUNIB","url":"https://clinicaltrials.gov/study/NCT03841201","created_at":"2021-01-18T18:57:47.456Z","updated_at":"2025-02-25T13:35:14.380Z","phase":"Phase 2","brief_title":"Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma","source_id_and_acronym":"NCT03841201 - IMMUNIB","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":"","alterations":" ","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-05-12"},{"id":"98f8a6d9-65fb-494a-8761-276771f22984","acronym":"","url":"https://clinicaltrials.gov/study/NCT05060796","created_at":"2021-09-29T11:53:48.510Z","updated_at":"2024-07-02T16:35:54.523Z","phase":"Phase 1","brief_title":"Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC","source_id_and_acronym":"NCT05060796","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • CXCL13","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2034","study_completion_date":" 11/01/2034","last_update_posted":"2023-02-28"},{"id":"aa427175-54cc-421c-9eb3-20e2eec8ad01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703375","created_at":"2021-01-18T18:08:54.175Z","updated_at":"2024-07-02T16:36:00.520Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","source_id_and_acronym":"NCT03703375","lead_sponsor":"Celgene","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2022-11-14"},{"id":"5fea2821-cde0-47c3-8a52-bc1bd9c134f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01807182","created_at":"2021-01-18T08:00:46.757Z","updated_at":"2024-07-02T16:36:00.634Z","phase":"Phase 2","brief_title":"Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01807182","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BRAF • CD8 • CD4 • CXCL13","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CD8 • CD4 • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 08/20/2013","start_date":" 08/20/2013","primary_txt":" Primary completion: 08/26/2021","primary_completion_date":" 08/26/2021","study_txt":" Completion: 08/26/2021","study_completion_date":" 08/26/2021","last_update_posted":"2022-11-10"},{"id":"8de501de-dc24-4c4c-b0d5-267b52f9ac57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04153799","created_at":"2021-01-18T20:16:16.281Z","updated_at":"2024-07-02T16:36:45.084Z","phase":"Phase 1","brief_title":"Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04153799","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • CXCL13","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR5 Modified EGFR Targeted CAR-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-05-12"},{"id":"1b538d58-e69e-4cb2-88ca-91d1700ceaba","acronym":"BIOMOG","url":"https://clinicaltrials.gov/study/NCT04202055","created_at":"2021-01-18T20:28:28.008Z","updated_at":"2024-07-02T16:36:52.321Z","phase":"","brief_title":"Immunologic Biomarker Profile of Cerebrospinal Fluid","source_id_and_acronym":"NCT04202055 - BIOMOG","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" IL6 • CXCL13 • IL10 • CD27 • CCL2 • IL17A • MMP9 • IL1B • VCAM1","pipe":"","alterations":" ","tags":["IL6 • CXCL13 • IL10 • CD27 • CCL2 • IL17A • MMP9 • IL1B • VCAM1"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 08/31/2019","primary_completion_date":" 08/31/2019","study_txt":" Completion: 08/31/2019","study_completion_date":" 08/31/2019","last_update_posted":"2019-12-17"},{"id":"18a31d2f-4fc8-4aec-b7b2-91da3287927e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273452","created_at":"2021-01-18T16:10:03.757Z","updated_at":"2024-07-02T16:37:17.600Z","phase":"Phase 2","brief_title":"Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)","source_id_and_acronym":"NCT03273452","lead_sponsor":"Qingdao University","biomarkers":" CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1","pipe":"","alterations":" ","tags":["CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • prednisone • Epidaza (chidamide) • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-09-25"},{"id":"d26c9a04-9e63-43fe-a9e5-b1046f5ac605","acronym":"","url":"https://clinicaltrials.gov/study/NCT01804712","created_at":"2021-01-18T07:59:49.284Z","updated_at":"2024-07-02T16:37:21.899Z","phase":"Phase 1","brief_title":"Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy","source_id_and_acronym":"NCT01804712","lead_sponsor":"Stephen Howell, M.D.","biomarkers":" CXCL13","pipe":"","alterations":" ","tags":["CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2017-05-19"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]